HC Wainwright Has Positive Forecast for Transcat Q2 Earnings

Transcat, Inc. (NASDAQ:TRNS) – HC Wainwright upped their Q2 2026 earnings estimates for Transcat in a note issued to investors on Wednesday, June 25th. HC Wainwright analyst S. Buck now forecasts that the scientific and technical instruments company will earn $0.43 per share for the quarter, up from their prior estimate of $0.26. HC Wainwright currently has a “Buy” rating and a $116.00 target price on the stock. The consensus estimate for Transcat’s current full-year earnings is $2.30 per share. HC Wainwright also issued estimates for Transcat’s Q3 2026 earnings at $0.38 EPS and FY2026 earnings at $1.87 EPS.

Transcat (NASDAQ:TRNS) last posted its quarterly earnings results on Monday, May 19th. The scientific and technical instruments company reported $0.64 EPS for the quarter, missing analysts’ consensus estimates of $0.66 by ($0.02). The company had revenue of $77.13 million during the quarter, compared to the consensus estimate of $76.40 million. Transcat had a return on equity of 6.47% and a net margin of 5.21%. The business’s revenue was up 8.8% compared to the same quarter last year.

Separately, Wall Street Zen upgraded shares of Transcat from a “sell” rating to a “hold” rating in a report on Wednesday, May 28th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $114.00.

Transcat Trading Down 0.6%

NASDAQ TRNS opened at $84.82 on Friday. The company’s 50-day moving average price is $82.59 and its 200-day moving average price is $85.53. The company has a current ratio of 2.29, a quick ratio of 1.87 and a debt-to-equity ratio of 0.11. The stock has a market cap of $790.52 million, a PE ratio of 54.37 and a beta of 0.75. Transcat has a 12 month low of $67.56 and a 12 month high of $147.12.

Institutional Trading of Transcat

Several hedge funds have recently modified their holdings of the company. Centiva Capital LP lifted its position in shares of Transcat by 6.0% during the fourth quarter. Centiva Capital LP now owns 3,009 shares of the scientific and technical instruments company’s stock valued at $318,000 after buying an additional 171 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Transcat by 0.6% during the first quarter. Bank of New York Mellon Corp now owns 27,916 shares of the scientific and technical instruments company’s stock valued at $2,078,000 after buying an additional 172 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Transcat by 3.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,137 shares of the scientific and technical instruments company’s stock valued at $543,000 after buying an additional 194 shares during the last quarter. Diamond Hill Capital Management Inc. lifted its position in shares of Transcat by 3.4% during the first quarter. Diamond Hill Capital Management Inc. now owns 6,353 shares of the scientific and technical instruments company’s stock valued at $473,000 after buying an additional 210 shares during the last quarter. Finally, US Bancorp DE lifted its position in shares of Transcat by 14.6% during the first quarter. US Bancorp DE now owns 1,770 shares of the scientific and technical instruments company’s stock valued at $132,000 after buying an additional 226 shares during the last quarter. 98.34% of the stock is owned by hedge funds and other institutional investors.

Transcat Company Profile

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.